Century Therapeutics, INC Schedule 13G passive stakes

Point72 Asset Management and Steven A. Cohen have reported a 3.3% beneficial ownership stake in Century Therapeutics, Inc.

RTW Investments, LP and Roderick Wong have reported a beneficial ownership of 7.1% in Century Therapeutics, Inc. common stock.

RA Capital Management and its affiliates have reported a 9.9% beneficial ownership stake in Century Therapeutics, Inc., following a recent private placement.

A group of Venrock entities and individuals has reported a 7.1% beneficial ownership stake in Century Therapeutics, Inc., primarily through common stock and warrants acquired in a recent private placement.

Commodore Capital LP and its affiliates have reported a 7.1% beneficial ownership stake in Century Therapeutics, Inc., including shares and warrants.

TCG Crossover Funds II and III, along with Chen Yu, have reported a combined beneficial ownership of 9.9% in Century Therapeutics, Inc. common stock.

Deep Track Capital and its affiliated funds have reported a passive beneficial ownership of 7.34% in Century Therapeutics, Inc., totaling 13,486,400 shares.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, reported a 5.4% beneficial ownership stake in Century Therapeutics, Inc.

Bain Capital Life Sciences Opportunities III, LP has filed an amendment disclosing its beneficial ownership of 4.1% of Century Therapeutics, Inc.'s common stock as of September 30, 2025.

Casdin Capital, LLC and Eli Casdin have filed an amended Schedule 13G, revealing a shared beneficial ownership of 3.7% in Century Therapeutics, Inc.'s common stock as of March 31, 2025.

A group of Venrock Healthcare Capital Partners entities and individuals have filed an amended Schedule 13G, reporting a continued beneficial ownership of 4.7% of Century Therapeutics, Inc.'s common stock as of December 31, 2024.